News
MTEM
0.5700
+1.79%
0.0100
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/23 21:31
Looking Into Molecular Templates's Return On Capital Employed
Benzinga · 12/22/2022 14:49
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting
AUSTIN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, ...
GlobeNewswire · 12/02/2022 22:02
BRIEF-Molecular Templates Inc - Co’S Common Shares Will Begin Trading On Nasdaq Capital Market Effective With Open Of Trading On December 2, 2022
Reuters · 12/02/2022 13:23
BRIEF-Molecular Templates Appointes Jason Kim, Co’s President & Chief Operating Officer As Interim CFO
Reuters · 12/01/2022 22:02
Molecular Therapeutics Says On Nov. 28, 2022 Interim CFO, Treasurer, SVP Sean McLennan Informed Co. Of Intent To Resign From Positions; Co. Appointed Jason Kim As Interim CFO
Benzinga · 12/01/2022 21:44
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/30/2022 21:32
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference
AUSTIN, Texas, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, ...
GlobeNewswire · 11/23/2022 21:30
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 11/17/2022 21:32
Molecular Templates Third Quarter 2022 Earnings: Beats Expectations
Molecular Templates ( NASDAQ:MTEM ) Third Quarter 2022 Results Key Financial Results Revenue: US$4.24m (up 78% from 3Q...
Simply Wall St. · 11/13/2022 12:39
Barclays Maintains Overweight on Molecular Templates, Lowers Price Target to $1
Benzinga · 11/11/2022 12:29
--Barclays Adjusts Price Target on Molecular Templates to $1 From $4.50, Maintains Overweight Rating
--Barclays Adjusts Price Target on Molecular Templates to $1 From $4.50, Maintains Overweight Rating
MT Newswires · 11/11/2022 10:58
Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates
Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of 8.33% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10/2022 22:55
Molecular Templates GAAP EPS of -$0.44 beats by $0.04, revenue of $4.24M beats by $1.16M
Seekingalpha · 11/10/2022 22:11
BRIEF-Molecular Templates Inc Reports Third Quarter 2022 Financial Results
Reuters · 11/10/2022 21:44
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $4.2M
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $4.2M
MT Newswires · 11/10/2022 16:38
Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
AUSTIN, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, ...
GlobeNewswire · 11/04/2022 15:00
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers
Benzinga · 09/08/2022 09:26
Molecular Templates Announces Participation in Four Upcoming Conferences
AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, e...
GlobeNewswire · 08/31/2022 20:52
Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2022
The analysts covering Molecular Templates, Inc. ( NASDAQ:MTEM ) delivered a dose of negativity to shareholders today...
Simply Wall St. · 08/17/2022 10:17
More
Webull provides a variety of real-time MTEM stock news. You can receive the latest news about Molecular Templates Inc through multiple platforms. This information may help you make smarter investment decisions.
About MTEM
Molecular Templates, Inc. is a clinical stage biopharmaceutical company that is focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer and other serious diseases. The Company utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The Company is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.